Patents by Inventor Patrice Gill

Patrice Gill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGONISTS OF ROR GAMMAt
    Publication number: 20230295087
    Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: May 8, 2020
    Publication date: September 21, 2023
    Inventors: Lalgudi S. Harikrishnan, Brian E. Fink, Patrice Gill, Lan-Ying Qin, Muthoni G. Kamau, Tram N. Huynh, Ashok Vinayak Purandare, Honghe Wan, Daniel O’Malley
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230144824
    Abstract: Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: May 11, 2023
    Inventors: Liqi HE, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Qiang CONG, Yam B. POUDEL, Prasanna SIVAPRAKASAM, Christine M. TARBY, Patrice GILL, Andrew F. DONNELL, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230127326
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 27, 2023
    Inventors: Christine M. TARBY, Qiang CONG, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Matthias BROEKEMA, Patrice GILL, Prasanna SIVAPRAKASAM, Walter L. JOHNSON, Murugaiah Andappan Murugaiah SUBBAIAH, Yam B. POUDEL
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230118688
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 20, 2023
    Inventors: Heng CHENG, Christine M. TARBY, Sanjeev GANGWAR, Ashvinikumar V. GAVAI, Walter L. JOHNSON, Yam B. POUDEL, Prasanna SIVAPRAKASAM, Patrice GILL, Andrew F. DONNELL, Murugaiah Andappan Murugaiah SUBBAIAH
  • NLRP3 MODULATORS
    Publication number: 20220257587
    Abstract: The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Application
    Filed: April 28, 2022
    Publication date: August 18, 2022
    Inventors: Daniel O'Malley, Ashvinkumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
  • NLRP3 modulators
    Patent number: 11344543
    Abstract: The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: May 31, 2022
    Assignee: Innate Tumor Immunity, Inc.
    Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
  • NLRP3 MODULATORS
    Publication number: 20220089571
    Abstract: The present invention provides compounds of Formula (I): Formula (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Application
    Filed: January 13, 2020
    Publication date: March 24, 2022
    Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Derek J. Norris, Hua Gong, Yong Zhang, Patrice Gill, Christine M. Tarby, Matthias Broekema, Scott Hunter Watterson
  • NLRP3 MODULATORS
    Publication number: 20220089566
    Abstract: The present invention provides compounds of Formula (I), (II) or (III): (I), (II), (III), wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Application
    Filed: January 20, 2020
    Publication date: March 24, 2022
    Inventors: SCOTT HUNTER WATTERSON, Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Steven P. Seitz, Hua Gong
  • NLRP3 MODULATORS
    Publication number: 20200129500
    Abstract: The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Application
    Filed: July 12, 2018
    Publication date: April 30, 2020
    Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
  • 5H-pyrido[3,2-B]indole compounds as anticancer agents
    Patent number: 10174024
    Abstract: The present invention is directed to tricyclic compounds of formula (I), pharmaceutically acceptable compositions comprising compounds of the invention and said compositions for use in methods for the treatment of various disorders in particular cancer.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: January 8, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wen-Ching Han, Andrew P. Degnan, Jeffrey A. Deskus, Ashvinikumar V. Gavai, Patrice Gill, William D. Schmitz, John E. Starrett, Jr.
  • 5H-PYRIDO[3,2-B]INDOLE COMPOUNDS AS ANTICANCER AGENTS
    Publication number: 20180093983
    Abstract: The present invention is directed to tricyclic compounds of formula (I), pharmaceutically acceptable compositions comprising compounds of the invention and said compositions for use in methods for the treatment of various disorders in particular cancer.
    Type: Application
    Filed: May 11, 2016
    Publication date: April 5, 2018
    Inventors: Wen-Ching HAN, Andrew P. Degnan, Jeffrey D. Deskus, Ashvinikumar V. Gavai, Patrice Gill, William D. Schmitz, John E. Starrett, JR.
  • Tricyclic compounds as anticancer agents
    Patent number: 9751879
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: September 5, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, Jr., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • Carbazole compounds useful as bromodomain inhibitors
    Patent number: 9492460
    Abstract: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: November 15, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Poss, David R. Tortolani, Dharmpal S. Dodd, Christopher P. Mussari, John S. Tokarski, Ashvinikumar V. Gavai, Yufen Zhao, George V. Delucca, Daniel O'Malley, Derek J. Norris, Patrice Gill, Claude A. Quesnelle, Wen-Ching Han
  • NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS
    Publication number: 20160326173
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: July 26, 2016
    Publication date: November 10, 2016
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, JR., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS
    Publication number: 20160318928
    Abstract: The present invention is directed to tricyclic compounds (I), pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: December 23, 2014
    Publication date: November 3, 2016
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, JR., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds
    Patent number: 9427442
    Abstract: Disclosed are compounds of Formula (I): (Formula (I)) wherein: R1 is —CH2CH2CF3; R2 is —CH2CH2CH2F, —CH2CF2CH3, —CH2CH2CF3, —CH2CH(CH3)CF3, —CH2CH2CF2CH3, (Formulae (II), (III), (IV), (V) or (VI): R3 is H or —CH3; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: August 30, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yufen Zhao, Ashvinikumar V. Gavai, Patrice Gill, Soong-Hoon Kim, Brian E. Fink, Libing Chen, Mark G. Saulnier, Wen-Ching Han
  • NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS
    Publication number: 20160176864
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: December 23, 2014
    Publication date: June 23, 2016
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, JR., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof
    Patent number: 9273014
    Abstract: Disclosed are compounds of Formula (I) and/or salts thereof: wherein R1 is —CH2CH2CF3; R2 is —CH2CH2CF3 or —CH2CH2CH2CF3; R3 is H, —CH3, or Rx; R4 is H or Ry; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer; or as prodrugs of such compounds.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: March 1, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, George V. DeLucca, Daniel O'Malley, Patrice Gill, Claude A. Quesnelle, Brian E. Fink, Yufen Zhao, Francis Y. Lee
  • N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds
    Patent number: 9242940
    Abstract: Disclosed are compounds of Formula (I): wherein: R1 is —CH2CH2CF3; R2 is —CH2CH2CF3, or —CH2CH2CH2CF3; R3 is —CH2CF3, —CH2CN, —CH2(cyclopropyl), pyridinyl, chloropyridinyl, or tetrahydropyranyl; Ring A is phenyl or pyridinyl; Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: January 26, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wen-Ching Han, Patrice Gill, Ashvinikumar V. Gavai, Claude A. Quesnelle
  • Substituted 1,5-benzodiazepinones compounds
    Patent number: 9187434
    Abstract: Disclosed are compounds of Formula (I): wherein: R1 is CH2CH2CF3; R2 is CH2CH2CF3, CH2(cyclopropyl), or phenyl; R3 is H or CH3; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: November 17, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Patrice Gill, Claude A. Quesnelle, Mark G. Saulnier, Ashvinikumar V. Gavai